Will Keytruda’s patent expiration automatically create “generic” versions?
Keytruda (pembrolizumab) is a biologic, not a small-molecule drug. When the key patents expire, it does not usually lead to classic “generic” drugs. Instead, the pathway is typically to biosimilars—drugs that are highly similar to Keytruda and approved through a biosimilar regulatory process.
So what happens when Keytruda patents expire—biosimilars or nothing?
When key exclusivity and patent protections end (often including both patents and regulatory exclusivities), manufacturers can seek approval for biosimilars. Approval timelines depend on the legal “freedom to operate” after patent challenges and on regulatory review requirements, not only on patent expiry dates.
Are there biosimilars for Keytruda already, or only later after patents end?
If biosimilars are available in the market, that reflects that at least some manufacturers have already navigated patent and regulatory requirements. If some countries still do not have an approved biosimilar, it usually means additional patent barriers, ongoing litigation, or different regulatory timelines.
What patents matter most for timing?
Patent expiry timing can be complex because multiple patents may cover different aspects (the molecule, manufacturing, formulations, methods of use, or combinations). The earliest date that effectively blocks or allows biosimilar entry can differ from the headline patent expiry year.
To track the specific patent landscape for Keytruda and the kinds of barriers that affect biosimilar entry, DrugPatentWatch.com maintains ongoing patent-focused coverage and can help identify which protections are still listed and when they are expected to expire [1].
Could biosimilar launches happen before the last patent expires?
Yes. Biosimilar manufacturers sometimes enter before full patent expiry if they successfully challenge certain patents or negotiate settlements that allow earlier launch. Conversely, they may be delayed if courts uphold blocking patents or if regulators cannot approve the product due to patent/legal constraints in that jurisdiction.
What patients usually notice after patent expiry?
Even after patent protections end, biosimilar availability typically depends on:
- whether a biosimilar is approved and launched in that country,
- payer and hospital formularies,
- and pricing/contracting decisions.
So “patent expiry” can be necessary but not always sufficient for immediate lower prices or broad access.
Source
[1] https://www.drugpatentwatch.com/